Lupus Agents: Benlysta (belimumab) and Saphnelo (anifrolumab-fnia) Vials
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization for Benlysta intravenous vial therapy under the MassHealth medical benefit for members with systemic lupus erythematosus or lupus nephritis. It also presents related criteria for Saphnelo vial therapy and applies to providers requesting coverage.
The Saphnelo vial criteria were revised to remove the requirement to step through Benlysta or document cutaneous systemic lupus erythematosus.
Benlysta lupus nephritis criteria added low-dose intravenous cyclophosphamide as an induction-treatment option and added specialist involvement requirements throughout the criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.